Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor
Tetsuya Taniguchi, Naoki Ashizawa, Koji Matsumoto, et al.
Journal of Pharmacology and Experimental Therapeutics (2019) Vol. 371, Iss. 1, pp. 162-170
Open Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9221-9221
Open Access | Times Cited: 345
Uric acid in health and disease: From physiological functions to pathogenic mechanisms
Shijie Wen, Hiroshi Arakawa, Ikumi Tamai
Pharmacology & Therapeutics (2024) Vol. 256, pp. 108615-108615
Closed Access | Times Cited: 70
Recent advances in gout drugs
Cheng Shi, Ziting Zhou, Xiaowei Chi, et al.
European Journal of Medicinal Chemistry (2022) Vol. 245, pp. 114890-114890
Closed Access | Times Cited: 45
Agents for the Treatment of Gout: Current Advances and Future Perspectives
Xiaoyi Zeng, Yajing Liu, Yuxin Fan, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 21, pp. 14474-14493
Closed Access | Times Cited: 24
The substrate and inhibitor binding mechanism of polyspecific transporter OAT1 revealed by high-resolution cryo-EM
Tong‐Yi Dou, Tengfei Lian, Shi Shu, et al.
Nature Structural & Molecular Biology (2023) Vol. 30, Iss. 11, pp. 1794-1805
Open Access | Times Cited: 23
Structural Basis for Inhibition of Urate Reabsorption in URAT1
Junping Fan, Wenjun Xie, Han Ke, et al.
JACS Au (2025) Vol. 5, Iss. 3, pp. 1308-1319
Open Access | Times Cited: 1
Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout
Eun Ha Kang, Eun Hye Park, Anna Shin, et al.
European Heart Journal (2021) Vol. 42, Iss. 44, pp. 4578-4588
Open Access | Times Cited: 46
Review of Urate-Lowering Therapeutics: From the Past to the Future
Christopher Jenkins, Jennifer H. Hwang, Jeffrey B. Kopp, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 36
A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 450-450
Open Access | Times Cited: 7
Recent approaches to gout drug discovery: an update
Naoyuki Otani, Motoshi Ouchi, Hideo Kudo, et al.
Expert Opinion on Drug Discovery (2020) Vol. 15, Iss. 8, pp. 943-954
Closed Access | Times Cited: 41
URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice
Yoshiro Tanaka, Tomohisa Nagoshi, H Takahashi, et al.
Molecular Metabolism (2021) Vol. 55, pp. 101411-101411
Open Access | Times Cited: 35
CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia
Zean Zhao, Jiang Yu, Yanyu Chen, et al.
Acta Pharmacologica Sinica (2021) Vol. 43, Iss. 1, pp. 121-132
Open Access | Times Cited: 34
Hypouricemia and Urate Transporters
Naoyuki Otani, Motoshi Ouchi, Kazuharu Misawa, et al.
Biomedicines (2022) Vol. 10, Iss. 3, pp. 652-652
Open Access | Times Cited: 27
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout
Zihan Hou, Aijinxiu Ma, Jiale Mao, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 12, pp. 895-909
Closed Access | Times Cited: 16
Uric acid transport, transporters, and their pharmacological targeting
Emmanuel A. Adomako, Orson W. Moe
Acta Physiologica (2023) Vol. 238, Iss. 2
Open Access | Times Cited: 14
Structural basis for the transport and substrate selection of human urate transporter 1
Jingjing He, Guoyun Liu, Fang Kong, et al.
Cell Reports (2024) Vol. 43, Iss. 8, pp. 114628-114628
Open Access | Times Cited: 6
Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout
Tomohiko Ishikawa, Toshinari Takahashi, Tetsuya Taniguchi, et al.
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 11, pp. 1397-1406
Open Access | Times Cited: 32
Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia
Zean Zhao, Jin Liu, Peihua Kuang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 229, pp. 114092-114092
Closed Access | Times Cited: 32
Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1/3 and ABCG2
Tetsuya Taniguchi, Koichi Omura, Keisuke Motoki, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 29
Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study
Hidekatsu Yanai, Hisayuki Katsuyama, Mariko Hakoshima, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 567-567
Open Access | Times Cited: 12
Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity
Junichiro Uda, Seiichi Kobashi, Sachiho Miyata, et al.
ACS Medicinal Chemistry Letters (2020) Vol. 11, Iss. 10, pp. 2017-2023
Open Access | Times Cited: 32
Omega-3 Polyunsaturated Fatty Acids Inhibit the Function of Human URAT1, a Renal Urate Re-Absorber
Hiroki Saito, Yu Toyoda, Tappei Takada, et al.
Nutrients (2020) Vol. 12, Iss. 6, pp. 1601-1601
Open Access | Times Cited: 30
OAT10/SLC22A13 Acts as a Renal Urate Re-Absorber: Clinico-Genetic and Functional Analyses With Pharmacological Impacts
Yu Toyoda, Yusuke Kawamura, Akiyoshi Nakayama, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 18
Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
Atsushi Tanaka, Isao Taguchi, Itaru Hisauchi, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 10
Molecular mechanisms of urate transport by the native human URAT1 and its inhibition by anti-gout drugs
Canrong Wu, Yong Zhang, Sanshan Jin, et al.
Cell Discovery (2025) Vol. 11, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top